Kazuko Hasegawa1, Kenji Kochi2, Hidenori Maruyama3, Osamu Konishi3, Shunji Toya3, Toshinari Odawara4. 1. Neurology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan. 2. Data Science, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan. 3. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan. 4. Health Management Center, Yokohama City University, Kanagawa, Japan.
Abstract
BACKGROUND: Although previous phase II and III clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with dementia with Lewy bodies (DLB), some differences in efficacy outcomes were observed between the trials. OBJECTIVE: We aimed to further examine the efficacy and safety of zonisamide in DLB patients with parkinsonism in a post hoc analysis of pooled data from the previous phase II and III trials. METHODS: Both trials featured a 4-week run-in period followed by a 12-week treatment period with a double-blind, placebo-controlled, parallel-group, randomized, multicenter trial design. In our pooled analysis, the primary outcome was the change in Unified Parkinson's Disease Rating Scale (UPDRS) part III total score. Other outcomes included the changes in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory-10 (NPI-10) scores, and the incidence of adverse events. RESULTS:Zonisamide significantly decreased the UPDRS part III total and individual motor symptom scores but did not affect the MMSE or NPI-10 scores at week 12. There was no difference in the incidence of adverse events between the zonisamide and placebo groups except for decreased appetite, which had an increased frequency in the zonisamide 50 mg group compared with placebo. CONCLUSION: Our findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia.
RCT Entities:
BACKGROUND: Although previous phase II and III clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with dementia with Lewy bodies (DLB), some differences in efficacy outcomes were observed between the trials. OBJECTIVE: We aimed to further examine the efficacy and safety of zonisamide in DLB patients with parkinsonism in a post hoc analysis of pooled data from the previous phase II and III trials. METHODS: Both trials featured a 4-week run-in period followed by a 12-week treatment period with a double-blind, placebo-controlled, parallel-group, randomized, multicenter trial design. In our pooled analysis, the primary outcome was the change in Unified Parkinson's Disease Rating Scale (UPDRS) part III total score. Other outcomes included the changes in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory-10 (NPI-10) scores, and the incidence of adverse events. RESULTS:Zonisamide significantly decreased the UPDRS part III total and individual motor symptom scores but did not affect the MMSE or NPI-10 scores at week 12. There was no difference in the incidence of adverse events between the zonisamide and placebo groups except for decreased appetite, which had an increased frequency in the zonisamide 50 mg group compared with placebo. CONCLUSION: Our findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia.
Authors: David J Burn; Elise N Rowan; Thais Minett; Jonathon Sanders; Pat Myint; Jonathon Richardson; Alan Thomas; Jane Newby; Jenny Reid; John T O'Brien; Ian G McKeith Journal: Mov Disord Date: 2003-08 Impact factor: 10.338
Authors: Ian McKeith; Jacobo Mintzer; Dag Aarsland; David Burn; Helen Chiu; Jiska Cohen-Mansfield; Dennis Dickson; Bruno Dubois; John E Duda; Howard Feldman; Serge Gauthier; Glenda Halliday; Brian Lawlor; Carol Lippa; Oscar L Lopez; João Carlos Machado; John O'Brien; Jeremy Playfer; Wayne Reid Journal: Lancet Neurol Date: 2004-01 Impact factor: 44.182
Authors: Ian G McKeith; Elise Rowan; Kristina Askew; Anitha Naidu; Louise Allan; Nicky Barnett; Debbie Lett; Urs P Mosimann; David Burn; John T O'Brien Journal: Am J Geriatr Psychiatry Date: 2006-07 Impact factor: 4.105
Authors: I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada Journal: Neurology Date: 2005-10-19 Impact factor: 9.910